Earnings Estimate Revisions for AtriCure This medical device maker is expected to earn -$0.61 per share for the fiscal year ending December 2025, which represents a year-over-year change of 9%.

AtriCure ( NASDAQ:ATRC ) Full Year 2024 Results Key Financial Results Revenue: US$465.3m (up 17% from FY 2023). Net... AtriCure (ATRC) might move higher on growing optimism about its earnings ...

CEO Michael Carrel emphasized that 2024 was a year of "continued growth," highlighted by achieving $465 million in revenue, representing a 17% increase. Key drivers included robust performances in ...

MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management ...

Canaccord raised the firm’s price target on AtriCure (ATRC) to $66 from $61 and keeps a Buy rating on the shares. The firm said they posted a solid Q4 and management raised the low-end of its ...

Rick Wise; Analyst; Stifel, Nicolaus & Co. Inc. Good afternoon, and welcome to AtriCure's fourth quarter and full year 2024 earnings conference call. This call is being recorded for replay purposes.

Stifel raised the firm’s price target on AtriCure (ATRC) to $48 from $36 and keeps a Buy rating on the shares. For 2025, AtriCure reiterated their January 13 initial revenue guidance of $517M-$ ...

AtriCure, Inc. (NASDAQ:ATRC – Get Free Report)’s share price traded down 6% during trading on Friday after an insider sold shares in the company.The stock traded as low as $34.61 and last ...

A stock is considered to be oversold if the RSI reading falls below 30. In trading on Monday, shares of AtriCure Inc (Symbol: ATRC) entered into oversold territory, hitting an RSI reading of 29.3 ...

Good afternoon, and welcome to AtriCure's Fourth Quarter and Full Year 2024 Earnings Conference Call. This call is being recorded for replay purposes. [Operator Instructions] I would now like to ...